Clinical Trial Update: A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema [Phase 1, Phase 2]

View source ↗

Summary

BioMarin's BMN 331 gene therapy trial for hereditary angioedema is described. The study is in Phase 1/2 and currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• BMN 331

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hereditary Angioedema, HAE | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING